Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors

prnasiaJune 22, 2021

Tag: HUTCHMED , surufatinib , pNETs

PharmaSources Customer Service